We are developing and evaluating a series of technologies to target the sources of inflammation and inflammatory processes in different kinds of therapeutic indications.

These technologies are developed according to different strategies: development of novel therapeutic agents or repositioning of marketed drugs.

4P001 is developed to treat congenital muscular dystrophies. Duchenne muscular dystrophy (DMD) is a neuromuscular congenital disease characterized by rapidly progressive muscle wasting, primarily affecting young boys, who have to start using wheelchairs after loss of walking capacity and experience serious collateral problems (cardiomyopathy and respiratory failure). At present date, there is no cure for DMD. 4P001 acts at the same time on several physiological processes occurring during the onset of DMD, by modulating fibrosis, inflammation and muscle regeneration at once. Preclinical studies show that 4P001 is able to ameliorate muscle environment and physiology in DMD, suggesting promising application also for other types of muscular dystrophies.

Osteoarthritis is a degenerative, chronic, inflammatory disease, resulting in the destruction of the joints. Osteoarthritis (OA) is the most common musculo-skeletal disease, it is anticipated that by 2050, 130 millions people will suffer from OA*. 4P 004 is being developed in an effort to help patients affected by this disease. At this stage, the proof-of-concept and proof-of-mechanism have been established and the product will now be evaluated for basic safety.




* Rachel Wittenauer, Lily Smith, and Kamal Aden. “Priority Medicines for Europe and the World “A Public Health Approach to Innovation”-Background Paper 6.12 Osteoarthritis“, 2013.